{"product_id":"prescribing-for-elderly-patients-isbn-9780470024287","title":"Prescribing for Elderly Patients","description":"\u003cul\u003e \u003cli\u003eA guide for doctors to quickly choose the right drugs in the right dose for the most important clinical problems in the elderly\u003c\/li\u003e \u003cli\u003ePrescribing medications for elderly patients is complex - this book gives clear advice on treatment regimes, drug interactions, adverse effects, and recommended dose changes\u003c\/li\u003e \u003cli\u003eProvides practical help with the problems that can arise in reaching an accurate diagnosis in the elderly, recommends clear treatment options, lists key drug interactions and side effects, and advises when to amend doses\u003c\/li\u003e \u003c\/ul\u003e  List of Contributors.  \u003cp\u003eForeword.\u003c\/p\u003e \u003cp\u003ePreface.\u003c\/p\u003e \u003cp\u003eAcknowledgement.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Clinical Pharmacology of Ageing\u003c\/b\u003e \u003ci\u003e(Arduino Mangoni, Paul Jansen and Stephen Jackson).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eEpidemiology.\u003c\/p\u003e \u003cp\u003eAge-related changes in pharmacokinetics.\u003c\/p\u003e \u003cp\u003eAge-related changes in pharmacodynamics.\u003c\/p\u003e \u003cp\u003eAdverse drug reactions and drug interactions.\u003c\/p\u003e \u003cp\u003eAdherence.\u003c\/p\u003e \u003cp\u003ePolypharmacy versus appropriate prescribing.\u003c\/p\u003e \u003cp\u003eOver-the-counter medicines.\u003c\/p\u003e \u003cp\u003ePrescribing audit.\u003c\/p\u003e \u003cp\u003eMedication review.\u003c\/p\u003e \u003cp\u003eUndertreatment.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Dementia, Delirium, Agitation and Behavioural Problems\u003c\/b\u003e \u003ci\u003e(Catherine Bryant).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eDementia.\u003c\/p\u003e \u003cp\u003eDelirium.\u003c\/p\u003e \u003cp\u003eAgitation and behavioural problems.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Depression in Elderly Patients\u003c\/b\u003e \u003ci\u003e(Richard Weeks, Ross Kalucy and Jo Hill).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eAetiology.\u003c\/p\u003e \u003cp\u003eSigns and symptoms.\u003c\/p\u003e \u003cp\u003eDiagnosis.\u003c\/p\u003e \u003cp\u003eTherapy.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Psychotic Illness in Elderly Patients\u003c\/b\u003e \u003ci\u003e(Ross Kalucy, Jo Hill and Richard Weeks).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eAetiology.\u003c\/p\u003e \u003cp\u003eSymptoms and signs.\u003c\/p\u003e \u003cp\u003eDiagnosis.\u003c\/p\u003e \u003cp\u003eTherapy.\u003c\/p\u003e \u003cp\u003eKey points.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Sleep Disorders in the Elderly: the Pros and Cons of Prescribing\u003c\/b\u003e \u003ci\u003e(R. Doug McEvoy and Karin S. Nyfort-Hansen).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eInsomnia.\u003c\/p\u003e \u003cp\u003eRestless legs syndrome and periodic limb movements of sleep.\u003c\/p\u003e \u003cp\u003eNocturnal leg cramps.\u003c\/p\u003e \u003cp\u003eREM behaviour disorder.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Stroke\u003c\/b\u003e \u003ci\u003e(Joseph A. Harbison and Gary A. Ford).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eAetiology.\u003c\/p\u003e \u003cp\u003eModifiable risk factors for stroke.\u003c\/p\u003e \u003cp\u003eTherapy.\u003c\/p\u003e \u003cp\u003eKey points.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Orthostatic Hypotension, Postprandial Hypotension and Syncope in Older Patients\u003c\/b\u003e \u003ci\u003e(René W.M.M. Jansen).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eOrthostatic hypotension in older patients.\u003c\/p\u003e \u003cp\u003eKey points.\u003c\/p\u003e \u003cp\u003ePostprandial hypotension in older patients.\u003c\/p\u003e \u003cp\u003eKey points.\u003c\/p\u003e \u003cp\u003eSyncope in older patients.\u003c\/p\u003e \u003cp\u003eKey points.\u003c\/p\u003e \u003cp\u003eGuidelines.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Parkinson’s Disease\u003c\/b\u003e \u003ci\u003e(Gerrit Tissingh and Erik Ch. Wolters).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eSymptoms and signs of PD.\u003c\/p\u003e \u003cp\u003eAetiology and pathology.\u003c\/p\u003e \u003cp\u003eDiagnosis.\u003c\/p\u003e \u003cp\u003eTherapy.\u003c\/p\u003e \u003cp\u003eKey points.\u003c\/p\u003e \u003cp\u003eLinks.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Epilepsy\u003c\/b\u003e \u003ci\u003e(John O. Willoughby, Joseph Frasca and Emma M. Whitham).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eAetiology.\u003c\/p\u003e \u003cp\u003eSymptoms and signs.\u003c\/p\u003e \u003cp\u003eDiagnosis.\u003c\/p\u003e \u003cp\u003eTherapy.\u003c\/p\u003e \u003cp\u003eNewer anti-epileptic drugs.\u003c\/p\u003e \u003cp\u003eSafety of anti-epileptic drugs.\u003c\/p\u003e \u003cp\u003eTherapy scheme of the advised drugs.\u003c\/p\u003e \u003cp\u003eClinically-important drug interactions within anti-epileptic drugs.\u003c\/p\u003e \u003cp\u003eClinically-important drug interactions with other drugs.\u003c\/p\u003e \u003cp\u003eImportant adverse effects.\u003c\/p\u003e \u003cp\u003eDrug withdrawal.\u003c\/p\u003e \u003cp\u003eKey points.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Hypertension\u003c\/b\u003e \u003ci\u003e(Sanjeev Khindri and Stephen Jackson).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eAetiology.\u003c\/p\u003e \u003cp\u003eSymptoms and signs.\u003c\/p\u003e \u003cp\u003eDiagnosis.\u003c\/p\u003e \u003cp\u003eInvestigation.\u003c\/p\u003e \u003cp\u003eTherapy.\u003c\/p\u003e \u003cp\u003eClinical pharmacology of antihypertensive therapy.\u003c\/p\u003e \u003cp\u003eKey points.\u003c\/p\u003e \u003cp\u003eLinks.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Lipid-Lowering in the Elderly Patient\u003c\/b\u003e \u003ci\u003e(Anthony S. Wierzbicki).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eAetiology.\u003c\/p\u003e \u003cp\u003eSymptoms and signs.\u003c\/p\u003e \u003cp\u003eDiagnosis.\u003c\/p\u003e \u003cp\u003eTherapy.\u003c\/p\u003e \u003cp\u003eStatins.\u003c\/p\u003e \u003cp\u003eFibrates.\u003c\/p\u003e \u003cp\u003eNicotinic acid.\u003c\/p\u003e \u003cp\u003eEzetimibe.\u003c\/p\u003e \u003cp\u003eBile acid sequestrants.\u003c\/p\u003e \u003cp\u003eOmega-3 fatty acids.\u003c\/p\u003e \u003cp\u003eGuidelines.\u003c\/p\u003e \u003cp\u003eKey points.\u003c\/p\u003e \u003cp\u003eLinks.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Acute Coronary Syndrome\u003c\/b\u003e \u003ci\u003e(Derek Yiu and Arduino Mangoni).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eAetiology.\u003c\/p\u003e \u003cp\u003eSymptoms and signs.\u003c\/p\u003e \u003cp\u003eDiagnosis.\u003c\/p\u003e \u003cp\u003eTherapy.\u003c\/p\u003e \u003cp\u003eTherapy scheme of the advised drugs.\u003c\/p\u003e \u003cp\u003eKey points.\u003c\/p\u003e \u003cp\u003eGuidelines.\u003c\/p\u003e \u003cp\u003eAcknowledgements.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Heart Failure\u003c\/b\u003e \u003ci\u003e(Arduino Mangoni).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eEpidemiology.\u003c\/p\u003e \u003cp\u003eAetiology.\u003c\/p\u003e \u003cp\u003eClinical presentation.\u003c\/p\u003e \u003cp\u003eDiagnosis.\u003c\/p\u003e \u003cp\u003eTherapy.\u003c\/p\u003e \u003cp\u003eKey points.\u003c\/p\u003e \u003cp\u003eGuidelines.\u003c\/p\u003e \u003cp\u003eAcknowledgements.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Atrial Fibrillation and Other Rhythm Disturbances in the Elderly\u003c\/b\u003e \u003ci\u003e(Abhay Bajpai, Irina Savelieva and A. John Camm).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eAtrial arrhythmias.\u003c\/p\u003e \u003cp\u003eThe epidemiology and cost of AF.\u003c\/p\u003e \u003cp\u003eThe mechanism of atrial tachyarrhythmias.\u003c\/p\u003e \u003cp\u003eSymptoms and signs.\u003c\/p\u003e \u003cp\u003eDiagnosis.\u003c\/p\u003e \u003cp\u003eClassification of AF.\u003c\/p\u003e \u003cp\u003eCauses of AF.\u003c\/p\u003e \u003cp\u003ePrinciples of management of AF.\u003c\/p\u003e \u003cp\u003eTreatment of acute onset AF.\u003c\/p\u003e \u003cp\u003eSuppression of paroxysms of AF.\u003c\/p\u003e \u003cp\u003eStrategies in persistent AF—rate versus rhythm control.\u003c\/p\u003e \u003cp\u003eRate control in permanent AF.\u003c\/p\u003e \u003cp\u003eRisk of stroke and antithrombotic therapy in AF.\u003c\/p\u003e \u003cp\u003eNon-pharmacological techniques to prevent thrombus formation.\u003c\/p\u003e \u003cp\u003eKey points.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Valvular Heart Disease\u003c\/b\u003e \u003ci\u003e(Andrew T. Elder).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eInfective endocarditis.\u003c\/p\u003e \u003cp\u003ePrevention of endocarditis.\u003c\/p\u003e \u003cp\u003eDiagnosis and treatment of endocarditis.\u003c\/p\u003e \u003cp\u003ePrevention of thromboembolism.\u003c\/p\u003e \u003cp\u003ePrevention of progression of degenerative valvular disease.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Anticoagulants for Thrombosis and Embolism in the Elderly\u003c\/b\u003e \u003ci\u003e(Alexander Gallus and Dolly Daniel).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eThe anticoagulants.\u003c\/p\u003e \u003cp\u003eThrombosis in the elderly and indications for anticoagulants.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 Haematological Disorders\u003c\/b\u003e \u003ci\u003e(Bryone J. Kuss and Sabria Alhashami).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eAnaemia.\u003c\/p\u003e \u003cp\u003eVitamin B12 and folic acid deficiencies.\u003c\/p\u003e \u003cp\u003eThrombocytopenia.\u003c\/p\u003e \u003cp\u003eMyelodysplastic syndromes.\u003c\/p\u003e \u003cp\u003eAcute leukaemia.\u003c\/p\u003e \u003cp\u003eLymphoproliferative conditions.\u003c\/p\u003e \u003cp\u003eMultiple myeloma.\u003c\/p\u003e \u003cp\u003eKey points.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 COPD and Asthma in the Elderly\u003c\/b\u003e \u003ci\u003e(Martin Connolly and Tina L. Davies)\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eRisk factors and triggers.\u003c\/p\u003e \u003cp\u003ePresentation and diagnosis.\u003c\/p\u003e \u003cp\u003eObjective tests.\u003c\/p\u003e \u003cp\u003eDifferential diagnoses.\u003c\/p\u003e \u003cp\u003eManagement of COPD and asthma.\u003c\/p\u003e \u003cp\u003eAcute asthma.\u003c\/p\u003e \u003cp\u003eManagement of exacerbations of COPD.\u003c\/p\u003e \u003cp\u003eManagement of stable COPD.\u003c\/p\u003e \u003cp\u003eConclusion.\u003c\/p\u003e \u003cp\u003eKey Points.\u003c\/p\u003e \u003cp\u003eLearning Resources.\u003c\/p\u003e \u003cp\u003eGuidelines.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e19 Pneumonia in the Elderly\u003c\/b\u003e \u003ci\u003e(Peter A. Frith and Karin S. Nyfort-Hansen).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eEpidemiology.\u003c\/p\u003e \u003cp\u003eAetiology and pathogenesis.\u003c\/p\u003e \u003cp\u003eSymptoms and signs.\u003c\/p\u003e \u003cp\u003eDiagnosis.\u003c\/p\u003e \u003cp\u003ePatient assessment.\u003c\/p\u003e \u003cp\u003eTherapy.\u003c\/p\u003e \u003cp\u003eImportant considerations for drug usage.\u003c\/p\u003e \u003cp\u003ePrevention.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e20 Therapeutic Aspects of Pulmonary Tuberculosis\u003c\/b\u003e \u003ci\u003e(Paul van den Brande).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003ePathogenesis.\u003c\/p\u003e \u003cp\u003ePresentation of tuberculosis in the elderly.\u003c\/p\u003e \u003cp\u003eDiagnosis of tuberculosis.\u003c\/p\u003e \u003cp\u003eTreatment of tuberculosis.\u003c\/p\u003e \u003cp\u003eTreatment of latent tuberculosis infection.\u003c\/p\u003e \u003cp\u003eKey points.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e21 Interstitial Lung Disease in the Elderly\u003c\/b\u003e \u003ci\u003e(Jeffrey Bowden).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003ePresentation of interstitial lung disease.\u003c\/p\u003e \u003cp\u003eParticular problems in the elderly.\u003c\/p\u003e \u003cp\u003eGeneral comments with regard to therapy.\u003c\/p\u003e \u003cp\u003eAssessing the response to therapy.\u003c\/p\u003e \u003cp\u003eDrugs used in ILD.\u003c\/p\u003e \u003cp\u003eTreatment for specific forms of lung disease.\u003c\/p\u003e \u003cp\u003eKey points.\u003c\/p\u003e \u003cp\u003eLinks.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e22 Lung Cancer in the Elderly\u003c\/b\u003e \u003ci\u003e(Jeffrey Bowden).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eAetiology.\u003c\/p\u003e \u003cp\u003eSymptoms and signs.\u003c\/p\u003e \u003cp\u003eDiagnosis and staging.\u003c\/p\u003e \u003cp\u003eGoals of therapy.\u003c\/p\u003e \u003cp\u003eChemotherapeutic agents.\u003c\/p\u003e \u003cp\u003eTreatment protocols for NSCLC.\u003c\/p\u003e \u003cp\u003eNon cytotoxic agents: EGFR Inhibitors.\u003c\/p\u003e \u003cp\u003eTreatment of small cell carcinoma.\u003c\/p\u003e \u003cp\u003eTreatment of mesothelioma.\u003c\/p\u003e \u003cp\u003eAnti-emetic therapy.\u003c\/p\u003e \u003cp\u003eKey Points.\u003c\/p\u003e \u003cp\u003eGuidelines.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e23 Nutritional Disorders and the Older Person\u003c\/b\u003e \u003ci\u003e(Robert K. Penhall and Renuka Visvanathan).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eObesity and the older person.\u003c\/p\u003e \u003cp\u003eNutritional frailty.\u003c\/p\u003e \u003cp\u003eUnder-nutrition in older people.\u003c\/p\u003e \u003cp\u003eScreening and assessment of under-nutrition.\u003c\/p\u003e \u003cp\u003eThe management of the under-nourished older person.\u003c\/p\u003e \u003cp\u003eMonitoring and change.\u003c\/p\u003e \u003cp\u003eConclusion.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e24 Mouth and Dental Disorders\u003c\/b\u003e \u003ci\u003e(Cees de Baat and Isaac van der Waal).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003ePeriodontal disease.\u003c\/p\u003e \u003cp\u003eDental caries.\u003c\/p\u003e \u003cp\u003eOdontogenic infections.\u003c\/p\u003e \u003cp\u003eAlveolar osteitis.\u003c\/p\u003e \u003cp\u003eXerostomia and hyposalivation.\u003c\/p\u003e \u003cp\u003eCandidiasis.\u003c\/p\u003e \u003cp\u003eAngular cheilitis.\u003c\/p\u003e \u003cp\u003eDenture stomatitis.\u003c\/p\u003e \u003cp\u003eBurning mouth syndrome.\u003c\/p\u003e \u003cp\u003eRecurrent aphthous stomatitis.\u003c\/p\u003e \u003cp\u003eRecurrent herpes simplex.\u003c\/p\u003e \u003cp\u003eOral lichen planus.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e25 Swallowing Disorders and Medication in the Elderly\u003c\/b\u003e \u003ci\u003e(Eddy Dejaeger).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eNormal deglutition.\u003c\/p\u003e \u003cp\u003eChanges with Age.\u003c\/p\u003e \u003cp\u003eAetiology of deglutition disorders.\u003c\/p\u003e \u003cp\u003eSymptoms and signs.\u003c\/p\u003e \u003cp\u003eDiagnosis.\u003c\/p\u003e \u003cp\u003eTherapy.\u003c\/p\u003e \u003cp\u003eDeglutition disorders and medication.\u003c\/p\u003e \u003cp\u003eKey points.\u003c\/p\u003e \u003cp\u003eLinks.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e26 Upper Gastrointestinal Disorders\u003c\/b\u003e \u003ci\u003e(Geoffrey S. Hebbard).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eGastrooesophageal reflux disease.\u003c\/p\u003e \u003cp\u003eOesophageal motility disorders.\u003c\/p\u003e \u003cp\u003eNon-cardiac chest pain.\u003c\/p\u003e \u003cp\u003eOesophageal infections.\u003c\/p\u003e \u003cp\u003ePill-induced oesophagitis.\u003c\/p\u003e \u003cp\u003ePeptic ulcer disease.\u003c\/p\u003e \u003cp\u003eGastritis.\u003c\/p\u003e \u003cp\u003eNon-ulcer dyspepsia.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e27 Gastric Emptying in Older Patients\u003c\/b\u003e \u003ci\u003e(Robert J. Fraser).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eAetiology of disturbed gastric motor function in ageing.\u003c\/p\u003e \u003cp\u003eSymptoms and signs.\u003c\/p\u003e \u003cp\u003eDiagnosis.\u003c\/p\u003e \u003cp\u003eTherapy.\u003c\/p\u003e \u003cp\u003eTherapy scheme of advised drugs for gastroparesis.\u003c\/p\u003e \u003cp\u003eKey points.\u003c\/p\u003e \u003cp\u003eGuidelines.\u003c\/p\u003e \u003cp\u003eEffect of healthy ageing on appetite regulation—anorexia of ageing.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e28 Lower Gastrointestinal Disorders\u003c\/b\u003e \u003ci\u003e(Daniel L. Worthley, Graeme P. Young and Robert J. Fraser).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eMalabsorption.\u003c\/p\u003e \u003cp\u003eInflammatory bowel disease.\u003c\/p\u003e \u003cp\u003eDiverticulosis.\u003c\/p\u003e \u003cp\u003eMesenteric ischaemia.\u003c\/p\u003e \u003cp\u003eConstipation.\u003c\/p\u003e \u003cp\u003eDiarrhoea and faecal incontinence.\u003c\/p\u003e \u003cp\u003eHaemorrhoids.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e29 Abdominal Malignancies\u003c\/b\u003e \u003ci\u003e(Sarah Zaidi and Guy Chung-Faye).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eEpidemiology.\u003c\/p\u003e \u003cp\u003eAetiology.\u003c\/p\u003e \u003cp\u003eSymptoms and signs.\u003c\/p\u003e \u003cp\u003eTherapy.\u003c\/p\u003e \u003cp\u003eChemotherapy.\u003c\/p\u003e \u003cp\u003eKey points.\u003c\/p\u003e \u003cp\u003eLinks.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e30 Liver Diseases in the Elderly\u003c\/b\u003e \u003ci\u003e(Réme Mountfield and Alan J. Wigg).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003ePhysiological changes associated with ageing.\u003c\/p\u003e \u003cp\u003eDrug induced liver disease.\u003c\/p\u003e \u003cp\u003eCirrhosis.\u003c\/p\u003e \u003cp\u003eAlcoholic liver disease.\u003c\/p\u003e \u003cp\u003eNon-alcoholic steatohepatitis (NASH).\u003c\/p\u003e \u003cp\u003eHepatitis C.\u003c\/p\u003e \u003cp\u003eHepatitis B.\u003c\/p\u003e \u003cp\u003eLiver transplantation.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e31 Disorders of the lower urinary tract\u003c\/b\u003e \u003ci\u003e(Adrian Wagg).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003ePathophysiology.\u003c\/p\u003e \u003cp\u003eIncontinence subtypes.\u003c\/p\u003e \u003cp\u003eTreatment cessation.\u003c\/p\u003e \u003cp\u003eAssessment with a bearing on drug addition or withdrawal.\u003c\/p\u003e \u003cp\u003eRectal examination.\u003c\/p\u003e \u003cp\u003eVaginal examination.\u003c\/p\u003e \u003cp\u003eThe pharmacological treatment of urinary incontinence.\u003c\/p\u003e \u003cp\u003eCognition and antimuscarincs.\u003c\/p\u003e \u003cp\u003eBladder outflow tract obstruction.\u003c\/p\u003e \u003cp\u003eOther pharmacological measures.\u003c\/p\u003e \u003cp\u003eStress urinary incontinence.\u003c\/p\u003e \u003cp\u003eSummary.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e32 Management of Benign Prostatic Hyperplasia in Elderly Men\u003c\/b\u003e \u003ci\u003e(Ming Liu and Gordon H. Muir).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAssessment.\u003c\/p\u003e \u003cp\u003eProstate specific antigen (PSA).\u003c\/p\u003e \u003cp\u003eUrinary retention.\u003c\/p\u003e \u003cp\u003eNocturnal frequency.\u003c\/p\u003e \u003cp\u003eTreatment.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e33 Management of Erectile Dysfunction in the Elderly\u003c\/b\u003e \u003ci\u003e(Kevin Dennison).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003ePrevalence and aetiology of ED.\u003c\/p\u003e \u003cp\u003ePhysical or psychogenic?\u003c\/p\u003e \u003cp\u003eDiagnosis and assessment of ed in primary care.\u003c\/p\u003e \u003cp\u003eTreatment options.\u003c\/p\u003e \u003cp\u003eKey points.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e34 Benign Gynaecological Disorders\u003c\/b\u003e \u003ci\u003e(Maria Vella, James Balmforth and Linda Cardozo).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eUrogenital atrophy.\u003c\/p\u003e \u003cp\u003eProlapse.\u003c\/p\u003e \u003cp\u003eTraditional anatomical site prolapse classification.\u003c\/p\u003e \u003cp\u003eUrinary incontinence.\u003c\/p\u003e \u003cp\u003eDetrusor overactivity.\u003c\/p\u003e \u003cp\u003eDrug therapies.\u003c\/p\u003e \u003cp\u003eLichen sclerosis.\u003c\/p\u003e \u003cp\u003eLichen planus.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e35 Breast Cancer in Elderly Patients\u003c\/b\u003e \u003ci\u003e(Bogda Koczwara).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003ePresentation and diagnosis—special considerations in elderly patients.\u003c\/p\u003e \u003cp\u003eManagement of breast cancer.\u003c\/p\u003e \u003cp\u003eManagement of early breast cancer.\u003c\/p\u003e \u003cp\u003eTreatment of advanced breast cancer.\u003c\/p\u003e \u003cp\u003eSupportive care during breast cancer treatment.\u003c\/p\u003e \u003cp\u003eBreast cancer therapeutics in an elderly patient.\u003c\/p\u003e \u003cp\u003eConclusion.\u003c\/p\u003e \u003cp\u003eKey points.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e36 Pharmacological Management of Endocrine\u003c\/b\u003e Conditions in the Elderly Patient \u003ci\u003e(Nikolai Petrovsky).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eDiabetes aetiology.\u003c\/p\u003e \u003cp\u003eDiabetes symptoms and signs.\u003c\/p\u003e \u003cp\u003eDiabetes diagnosis.\u003c\/p\u003e \u003cp\u003eType 2 diabetes management.\u003c\/p\u003e \u003cp\u003ePharmacokinetic and pharmacodynamic data of diabetes medications in elderly patients.\u003c\/p\u003e \u003cp\u003eClinically important drug interactions within diabetes drugs.\u003c\/p\u003e \u003cp\u003eGeneral adverse effects of diabetes medications in elderly patients.\u003c\/p\u003e \u003cp\u003eSpecific adverse effects and clinically-important drug interactions of diabetes drugs.\u003c\/p\u003e \u003cp\u003ePituitary adenomas.\u003c\/p\u003e \u003cp\u003eThyroid disease.\u003c\/p\u003e \u003cp\u003eHyperparathyroidism.\u003c\/p\u003e \u003cp\u003eHormone replacement.\u003c\/p\u003e \u003cp\u003eEndocrine disease in the elderly—key points.\u003c\/p\u003e \u003cp\u003eFurther Reading.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e37 Rheumatoid Arthritis, Osteoarthritis, Polymyalgia Rheumatica, Gout and Pseudogout\u003c\/b\u003e \u003ci\u003e(E. Michael Shanahan and Stephen Hedger).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eRheumatoid arthritis.\u003c\/p\u003e \u003cp\u003eKey points in rheumatoid arthritis.\u003c\/p\u003e \u003cp\u003eOsteoarthritis.\u003c\/p\u003e \u003cp\u003eKey points in osteoarthritis.\u003c\/p\u003e \u003cp\u003ePolymyalgia rheumatica.\u003c\/p\u003e \u003cp\u003eKey points in PMR.\u003c\/p\u003e \u003cp\u003eGout and calcium pyrophosphate disease (CPPD).\u003c\/p\u003e \u003cp\u003eKey points in gout and CPPD.\u003c\/p\u003e \u003cp\u003eLinks.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e38 Falls, Osteoporosis, Paget’s Disease and Osteomalacia\u003c\/b\u003e \u003ci\u003e(Harald J.J. Verhaar and Paul Jansen).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eFalls and osteoporosis.\u003c\/p\u003e \u003cp\u003ePaget’s disease.\u003c\/p\u003e \u003cp\u003eOsteomalacia.\u003c\/p\u003e \u003cp\u003eKey points.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e39 Drugs and Falls\u003c\/b\u003e \u003ci\u003e(Nathalie van der Velde and Tischa J.M. van der Cammen).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003ePathophysiology.\u003c\/p\u003e \u003cp\u003eFall-risk-increasing drugs.\u003c\/p\u003e \u003cp\u003eClinical approach.\u003c\/p\u003e \u003cp\u003eTreatment: drug withdrawal.\u003c\/p\u003e \u003cp\u003eKey points.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e40 Pressure Ulcers\u003c\/b\u003e \u003ci\u003e(Rob J. van Marum).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eThe role of pressure in pressure ulcer development.\u003c\/p\u003e \u003cp\u003eThe role of nutrition in pressure ulcer development.\u003c\/p\u003e \u003cp\u003eRisk assessment.\u003c\/p\u003e \u003cp\u003ePrevention.\u003c\/p\u003e \u003cp\u003eLocal treatment.\u003c\/p\u003e \u003cp\u003eKey points.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e41 Leg Ulceration\u003c\/b\u003e \u003ci\u003e(Gabrielle M. McMullin).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eAetiology.\u003c\/p\u003e \u003cp\u003eSymptoms and signs.\u003c\/p\u003e \u003cp\u003eDiagnosis.\u003c\/p\u003e \u003cp\u003eTherapy.\u003c\/p\u003e \u003cp\u003eKey points.\u003c\/p\u003e \u003cp\u003eGuidelines.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e42 Xerosis and Asteatotic Eczema\u003c\/b\u003e \u003ci\u003e(Michael Yeung and Daniel Creamer).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eXerosis.\u003c\/p\u003e \u003cp\u003eActinic keratoses and Bowen’s disease.\u003c\/p\u003e \u003cp\u003eBullous pemphigoid\u003c\/p\u003e \u003cp\u003eCandidiasis.\u003c\/p\u003e \u003cp\u003eErysipelas and cellulitis.\u003c\/p\u003e \u003cp\u003eContact dermatitis.\u003c\/p\u003e \u003cp\u003eHerpes zoster (shingles).\u003c\/p\u003e \u003cp\u003eLichen planus.\u003c\/p\u003e \u003cp\u003eMalignant melanoma.\u003c\/p\u003e \u003cp\u003eMycosis fungoides.\u003c\/p\u003e \u003cp\u003eBasal cell carcinoma and squamous cell carcinoma.\u003c\/p\u003e \u003cp\u003ePsoriasis.\u003c\/p\u003e \u003cp\u003eScabies.\u003c\/p\u003e \u003cp\u003eTinea.\u003c\/p\u003e \u003cp\u003eUrticaria and angio-oedema.\u003c\/p\u003e \u003cp\u003eVenous eczema and the dependency syndrome.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e43 Age-Related Eye Diseases\u003c\/b\u003e \u003ci\u003e(Genevieve Larkin).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eCataract.\u003c\/p\u003e \u003cp\u003eGlaucoma.\u003c\/p\u003e \u003cp\u003eAge related macular degeneration.\u003c\/p\u003e \u003cp\u003eDiabetic retinopathy.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e44 Ear Disorders\u003c\/b\u003e \u003ci\u003e(Wynia Derks and Gerrit Hordijk).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eHearing loss.\u003c\/p\u003e \u003cp\u003eTinnitus.\u003c\/p\u003e \u003cp\u003eExternal otitis.\u003c\/p\u003e \u003cp\u003eDrugs causing hearing problems.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e45 Pain\u003c\/b\u003e \u003ci\u003e(Albert J.M. van Wijck).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eAetiology.\u003c\/p\u003e \u003cp\u003eDiagnosis.\u003c\/p\u003e \u003cp\u003eTherapy.\u003c\/p\u003e \u003cp\u003eKey points.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003e\u003cb\u003e46 Palliative Care in the Elderly\u003c\/b\u003e \u003ci\u003e(Alexander de Graeff and Saskia Teunissen).\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction.\u003c\/p\u003e \u003cp\u003eSymptoms.\u003c\/p\u003e \u003cp\u003ePalliative care in the elderly.\u003c\/p\u003e \u003cp\u003eTreatment of common symptoms in elderly patients.\u003c\/p\u003e \u003cp\u003eReferences.\u003c\/p\u003e \u003cp\u003eIndex.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eProfessor Stephen Jackson\u003c\/b\u003e, Professor of Geriatric Medicine, King's College London, UK.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eDr Paul Jansen\u003c\/b\u003e, Department of Geriatric Medicine, University Medical Centre Utrecht, The Netherlands.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eDr Arduino Mangoni\u003c\/b\u003e, Senior Lecturer and Consultant Physician in Clinical Pharmacology, Flinders University, Adelaide, Australia.\u003c\/p\u003e  Prescribing for elderly patients is complex and challenging. There is a higher incidence of co-morbidities, and an increased likelihood that the patient will already be on other medication. There are also complex drug interactions that need to be monitored, and an increased risk of adverse effects due to differences in drug distribution and clearance.  \u003cp\u003eThis book is specifically designed to provide comprehensive information to assist health care professionals in diagnosing and managing common geriatric conditions effectively and safely. Age-related changes in pharmacokinetics are clearly illustrated in tabular format, and treatment algorithms are derived from a thorough evidence-based review of the literature and the latest guidelines.\u003c\/p\u003e \u003cp\u003eEach chapter\u003c\/p\u003e \u003cul\u003e \u003cli\u003eprovides practical information on the problems that can arise in reaching an accurate diagnosis in elderly patients\u003c\/li\u003e \u003c\/ul\u003e \u003cul\u003e \u003cli\u003erecommends clear treatment options\u003c\/li\u003e \u003c\/ul\u003e \u003cul\u003e \u003cli\u003elists key drug interactions and side effects, and advises when to amend doses\u003c\/li\u003e \u003c\/ul\u003e \u003cul\u003e \u003cli\u003econtains key references and a list of selected websites linked to professional national and international organisations and guideline groups\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003e\u003ci\u003ePrescribing for Elderly Patients\u003c\/i\u003e is invaluable for consultants in geriatric medicine, specialist registrars and other trainees, general physicians (internists), clinical pharmacologists, and any clinicians working regularly with elderly patients. It is also useful as a quick reference guide for nurses and clinical pharmacists.\u003c\/p\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47989842346213,"sku":"NP9780470024287","price":173.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9780470024287.jpg?v=1761785650","url":"https:\/\/k12savings.com\/products\/prescribing-for-elderly-patients-isbn-9780470024287","provider":"K12savings","version":"1.0","type":"link"}